Qu Tian1, Susan M Resnick2, Stephanie A Studenski3, Luigi Ferrucci4. 1. Longitudinal Studies Section, Translational Gerontology Branch, National Institute on Aging, Baltimore, MD. Electronic address: qu.tian@nih.gov. 2. Laboratory of Behavioral Neuroscience, National Institute on Aging, Baltimore, MD. 3. Longitudinal Studies Section, Translational Gerontology Branch, National Institute on Aging, Baltimore, MD. 4. Longitudinal Studies Section, Translational Gerontology Branch, National Institute on Aging, Baltimore, MD. Electronic address: FerrucciLu@grc.nia.nih.gov.
Abstract
OBJECTIVES: To determine whether the trajectory of preclinical lap time variability from a 400-m walk differentiates participants with future mild cognitive impairment (MCI)/Alzheimer's disease (AD) from matched controls. DESIGN: A case-control retrospective study embedded in a large longitudinal cohort study, the Baltimore Longitudinal Study of Aging (BLSA). SETTING: In the BLSA, participants were scheduled for clinical visits, including mobility and cognitive assessments. Data reported here were collected between April 2007 and September 2017 (average follow-up 5.2 ± 2.4 years). PARTICIPANTS: 67 participants developed MCI/AD and 134 age- and sex-matched controls remained cognitively normal. MEASUREMENTS: Diagnoses of MCI and AD were adjudicated at a consensus conference. The rate of change in lap time variability between MCI/AD cases prior to symptom onset and controls were compared using mixed effects linear regression, and adjusted for baseline executive function, memory, gait speed, and changes in gait speed. RESULTS: Compared to controls, eventual MCI/AD cases had a greater rate of increase in lap time variability prior to symptom onset (β = 0.59, P = .009). This association was independent of baseline cognition, gait speeds at baseline or change over time from a 6-m or 400-m walk. CONCLUSION/IMPLICATIONS: Independent of other early indicators and gait slowing, a greater rate of increase in lap time variability from a 400-m walk differentiates individuals who eventually develop MCI/AD from controls, suggesting that early pathology affects the automaticity of walking. Lap time variability can be assessed during routine clinical practice over time and might help identify individuals at risk for future MCI/AD. Published by Elsevier Inc.
OBJECTIVES: To determine whether the trajectory of preclinical lap time variability from a 400-m walk differentiates participants with future mild cognitive impairment (MCI)/Alzheimer's disease (AD) from matched controls. DESIGN: A case-control retrospective study embedded in a large longitudinal cohort study, the Baltimore Longitudinal Study of Aging (BLSA). SETTING: In the BLSA, participants were scheduled for clinical visits, including mobility and cognitive assessments. Data reported here were collected between April 2007 and September 2017 (average follow-up 5.2 ± 2.4 years). PARTICIPANTS: 67 participants developed MCI/AD and 134 age- and sex-matched controls remained cognitively normal. MEASUREMENTS: Diagnoses of MCI and AD were adjudicated at a consensus conference. The rate of change in lap time variability between MCI/AD cases prior to symptom onset and controls were compared using mixed effects linear regression, and adjusted for baseline executive function, memory, gait speed, and changes in gait speed. RESULTS: Compared to controls, eventual MCI/AD cases had a greater rate of increase in lap time variability prior to symptom onset (β = 0.59, P = .009). This association was independent of baseline cognition, gait speeds at baseline or change over time from a 6-m or 400-m walk. CONCLUSION/IMPLICATIONS: Independent of other early indicators and gait slowing, a greater rate of increase in lap time variability from a 400-m walk differentiates individuals who eventually develop MCI/AD from controls, suggesting that early pathology affects the automaticity of walking. Lap time variability can be assessed during routine clinical practice over time and might help identify individuals at risk for future MCI/AD. Published by Elsevier Inc.
Entities:
Keywords:
Alzheimer's disease; Gait; automaticity; early diagnosis; epidemiology
Authors: Benjamin R Williams; David F Hultsch; Esther H Strauss; Michael A Hunter; Rosemary Tannock Journal: Neuropsychology Date: 2005-01 Impact factor: 3.295
Authors: Qu Tian; Luigi Ferrucci; Susan M Resnick; Eleanor M Simonsick; Michelle D Shardell; Bennett A Landman; Vijay K Venkatraman; Christopher E Gonzalez; Stephanie A Studenski Journal: Brain Imaging Behav Date: 2016-09 Impact factor: 3.978
Authors: Qu Tian; Susan M Resnick; Bennett A Landman; Yuankai Huo; Vijay K Venkatraman; Christopher E Gonzalez; Eleanor M Simonsick; Michelle D Shardell; Luigi Ferrucci; Stephanie A Studenski Journal: Exp Gerontol Date: 2016-02-17 Impact factor: 4.032
Authors: Sonja Vestergaard; Kushang V Patel; Stefania Bandinelli; Luigi Ferrucci; Jack M Guralnik Journal: Rejuvenation Res Date: 2009-06 Impact factor: 4.663
Authors: Nuria Marín-Jiménez; Carolina Cruz-León; Alejandro Perez-Bey; Julio Conde-Caveda; Alberto Grao-Cruces; Virginia A Aparicio; José Castro-Piñero; Magdalena Cuenca-García Journal: J Clin Med Date: 2022-01-10 Impact factor: 4.241